Wuhan Hiteck Biological Pharma News

Hyte Biotech (300683) 2020 Semi-Annual Report Review: Multiple Factors Influence Current Performance and Optimistic CRO and Innovative Drug Businesses

萬聯證券Sep 1, 2020 11:00

Haitian organism (300683): excellent clinical results in phase Ⅲ of CPT continue to follow-up progress.

萬聯證券Jun 16, 2020 11:00

Haite Biology (300683): the epidemic affects short-term performance and the direction of strategic transformation remains unchanged.

萬聯證券Apr 28, 2020 11:00

Haiter Biology (300683) comment report: phase CPT III clinical results blinded the annual performance is in line with expectations

萬聯證券Mar 3, 2020 10:00

Hite Biology (300683): policy-affected performance decline multiple myeloma drug CPT phase 3 clinical blindness prospect

長城國瑞證券Mar 1, 2020 10:00

Haight Biology (300683) in-depth report: positive Strategic Transformation CPTIII unveiling Blind is highly anticipated

萬聯證券Feb 5, 2020 10:00

Haite biology (300683): Jin Lujie sells pressurized multiple myeloma drugs at the end of clinical practice.

長城國瑞證券Jan 1, 2020 10:00

Hyte Creature (300683): Wait for the flowers to bloom

華融證券Jun 16, 2019 11:00

Hyte Biotech (300683) IPO Research Report: A Leading Biopharmaceutical Company in the Field of Neurorepair

興業證券Jul 30, 2017 11:00

Haite Biological (300683) New share Inquiry report

華鑫證券Jul 18, 2017 11:00